Search

Your search keyword '"Nicolas, Johny"' showing total 204 results
Start Over Author "Nicolas, Johny" Search Limiters Available in Library Collection
204 results on '"Nicolas, Johny"'

1. Prognostic value of high-sensitivity C-reactive protein among chronic kidney disease patients undergoing percutaneous coronary intervention

Author

Jones, Davis, Spirito, Alessandro, Sartori, Samantha, Smith, Kenneth F., Pivato, Carlo Andrea, Chiarito, Mauro, Cao, Davide, Nicolas, Johny, Beerkens, Frans, Edens, Madison, Pileggi, Brunna, Sen, Ananya, Zhang, Zhongjie, Vogel, Birgit, Sweeny, Joseph, Baber, Usman, Dangas, George, Sharma, Samin K., Kini, Annapoorna, and Mehran, Roxana

Published
2023
Full Text
View/download PDF

2. Clopidogrel Versus Aspirin as Monotherapy Following Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome Receiving a Drug‐Eluting Stent: A Systematic Literature Review and Meta‐Analysis.

Author

Sibbing, Dirk, Nicolas, Johny, Spirito, Alessandro, Vogel, Birgit, Cao, Davide, Stipek, Wanda, Kasireddy, Ellen, Qian, Andi, Khan, Irfan, and Mehran, Roxana

Subjects
PLATELET aggregation inhibitors, ACUTE coronary syndrome, MAJOR adverse cardiovascular events, ANGINA pectoris, RANDOMIZED controlled trials
Abstract

Objective: This study aimed to evaluate the comparative effectiveness and safety of clopidogrel versus aspirin as monotherapy following adequate dual antiplatelet therapy (DAPT) in patients with acute coronary syndrome (ACS). Methods: MEDLINE, Embase, and CENTRAL were searched from database inception to September 1, 2023. Randomized controlled trials (RCTs) and observational studies evaluating the effectiveness or safety of clopidogrel versus aspirin as monotherapy following DAPT in patients with ACS who received a drug‐eluting stent were included. Random‐effects meta‐analyses were conducted to compare risks of major adverse cardiovascular events (MACE) and clinically relevant bleeding. Results: Of 6242 abstracts identified, three unique studies were included: one RCT and two retrospective cohort studies. Studies included a total of 7081 post‐percutaneous coronary intervention ACS patients, 4260 of whom received aspirin monotherapy and 2821 received clopidogrel monotherapy. Studies included variable proportions of patients with ST‐elevation myocardial infarction (STEMI), non‐STEMI, and unstable angina. From the meta‐analysis, clopidogrel was associated with a 28% reduction in the risk of MACE compared with aspirin (hazard ratio [HR]: 0.72; 95% confidence interval [CI]: 0.54, 0.98), with no significant difference in clinically relevant bleeding (HR: 0.92; 95% CI: 0.68, 1.24). Conclusion: Despite the paucity of published evidence on the effectiveness and safety of clopidogrel versus aspirin in patients with ACS post‐drug‐eluting stent implantation, this meta‐analysis suggests that clopidogrel versus aspirin may result in a lower risk of MACE, with a similar risk of major bleeding. The present results are hypothesis‐generating and further large RCTs comparing antiplatelet monotherapy options in ACS patients are warranted. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. Abstract 14790: Impact of Pre-Frailty and Frailty in Women Undergoing TAVR: Insights From the WIN-TAVI Registry

Author

Petrovic, Marija, Spirito, Alessandro, Sartori, Samantha, Snyder, Clayton, Vogel, Birgit, Nicolas, Johny, Cohen, Rebecca M, Cao, Davide, Tchetche, Didier, Petronio, Anna S, Mehilli, Julinda, Lefevre, Thierry, Presbitero, Patrizia, Capranzano, Piera, IADANZA, ALESSANDRO, Sardella, Gennaro, Van Mieghem, Nicolas M, meliga, emanuele, DUMONTEIL, Nicolas, Fraccaro, Chiara, Trabattoni, Daniela, Mikhail, Ghada, Ferrer-Gracia, Maria-Cruz, Naber, Christoph, Kievit, Peter C, Sharma, Samin K, Morice, Marie C, Dangas, George, Chieffo, Alaide, and Mehran, Roxana

Published
2022
Full Text
View/download PDF

6. Abstract 12805: Incidence and Predictors of Myocardial Infarction or Stent Thrombosis in High-Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention

Author

Nicolas, Johny, Spirito, Alessandro, Sartori, Samantha, Zhang, Zhongjie, Pitaro, Nicholas, Cao, Davide, Vogel, Birgit, Beerkens, Frans, Youssef, David, Jones, Davis, Edens, Madison, Feldman, Daniel, Camaj, Anton, Power, David, Sweeny, Joseph, Sharma, Samin K, Kini, Annapoorna, Dangas, George, and Mehran, Roxana

Published
2022
Full Text
View/download PDF

10. Colchicine in Cardiovascular Disease: In-Depth Review

Author

Deftereos, Spyridon G., Beerkens, Frans J., Shah, Binita, Giannopoulos, George, Vrachatis, Dimitrios A., Giotaki, Sotiria G., Siasos, Gerasimos, Nicolas, Johny, Arnott, Clare, Patel, Sanjay, Parsons, Mark, Tardif, Jean-Claude, Kovacic, Jason C., and Dangas, George D.

Published
2022
Full Text
View/download PDF

11. TCT-168 Clinical Significance of Insulin- and Noninsulin-Dependent Diabetes in Patients Undergoing Percutaneous Revascularization of the Left Main Coronary Artery

Author

Roumeliotis, Anastasios, primary, Sartori, Samantha, additional, Power, David, additional, Vavouranakis, Emmanouil, additional, Tsioufis, Konstantinos, additional, Cao, Davide, additional, Oikonomou, Evangelos, additional, Nicolas, Johny, additional, Smith, Kenneth, additional, Sweeny, Joseph, additional, Sharma, Samin, additional, Kini, Annapoorna, additional, Mehran, Roxana, additional, and Dangas, George, additional

Published
2023
Full Text
View/download PDF

12. TCT-511 Impact of Adjunctive Intravascular Imaging on Cardiovascular Outcomes in Unprotected Left Main Percutaneous Coronary Intervention at a High-Volume Center

Author

Power, David, primary, Roumeliotis, Anastasios, additional, Camaj, Anton, additional, Nicolas, Johny, additional, Sartori, Samantha, additional, Smith, Kenneth, additional, Beerkens, Frans, additional, Edens, Madison, additional, Tanner, Richard, additional, Minatoguchi, Shingo, additional, Yasumura, Keisuke, additional, Dhulipala, Vishal, additional, Suleman, Javed, additional, Vogel, Birgit, additional, Hooda, Amit, additional, Kapur, Vishal, additional, Sharma, Raman, additional, Krishnamoorthy, Parasuram, additional, Sweeny, Joseph, additional, Kini, Annapoorna, additional, Sharma, Samin, additional, Mehran, Roxana, additional, and Dangas, George, additional

Published
2023
Full Text
View/download PDF

13. Impact of chronic kidney disease and diabetes on clinical outcomes in women undergoing PCI

Author

Spirito, Alessandro, primary, Itchhaporia, Dipti, additional, Sartori, Samantha, additional, Camenzind, Edoardo, additional, Chieffo, Alaide, additional, Dangas, George D., additional, Galatius, Soren, additional, Jeger, Raban V., additional, Kandzari, David E., additional, Kastrati, Adnan, additional, Kim, Hyo-Soo, additional, Kimura, Takeshi, additional, Leon, Martin B., additional, Mehta, Laxmi S., additional, Mikhail, Ghada W., additional, Morice, Marie-Claude, additional, Nicolas, Johny, additional, Pileggi, Brunna, additional, Serruys, Patrick W., additional, Smits, Pieter C., additional, Steg, P. Gabriel, additional, Stone, Gregg W., additional, Valgimigli, Marco, additional, Vogel, Birgit, additional, von Birgelen, Clemens, additional, Weisz, Giora, additional, Wijns, William, additional, Windecker, Stephan, additional, and Mehran, Roxana, additional

Published
2023
Full Text
View/download PDF

14. F-49 | Long term outcomes according to lesion location and SYNTAX points, not attributed to the left main lesion, in patients undergoing percutaneous coronary intervention of the left main coronary artery

Author

Roumeliotis, Anastasios, Power, David A., Sartori, Samantha, Vogel, Birgit, Nicolas, Johny, Smith, Kenneth, Sweeny, Joseph, Krishnan, Prakash, Hooda, Amit, Suleman, Javed, Sharma, Raman, Krishnamoorthy, Parasuram Melarcode, Dangas, George D., Sharma, Samin K., Kini, Annapoorna S., and Mehran, Roxana

Published
2024
Full Text
View/download PDF

16. Abstract 16570: Systemic Inflammation Alters the Bleeding-Ischemic Balance in High-Bleeding Risk Patients Undergoing Percutaneous Coronary Interventions

Author

Nicolas, Johny, Cao, Davide, Claessen, Bimmer E, Chiarito, Mauro, Sartori, Samantha, Qiu, Hanbo, Nardin, Matteo, Camaj, Anton, Roumeliotis, Anastasios, Zhang, Zhongjie, Goel, Ridhima, Chandiramani, Rishi, Baber, Usman, Sweeny, Joseph, Krishnan, Prakash, Kini, Annapoorna, Sharma, Samin K, Dangas, George, and Mehran, Roxana

Published
2020
Full Text
View/download PDF

18. Abstract 16507: Complex Percutaneous Coronary Intervention Features Worsen Prognosis in Diabetic Patients: Insights From a Large Single-center Registry

Author

Nicolas, Johny, Cao, Davide, Claessen, Bimmer E, Chiarito, Mauro, Sartori, Samantha, Qiu, Hanbo, Nardin, Matteo, Power, David, Roumeliotis, Anastasios, Goel, Ridhima, Chandiramani, Rishi, Zhang, Zhongjie, Baber, Usman, Sweeny, Joseph, Krishnan, Prakash, Kini, Annapoorna, Sharma, Samin K, Dangas, George, and Mehran, Roxana

Published
2020
Full Text
View/download PDF

22. IMPACT OF BODY SURFACE AREA ON OUTCOMES IN WOMEN AND MEN UNDERGOING PERCUTANEOUS CORONARY INTERVENTION

Author

Mehran, Roxana, primary, Edens, Madison, additional, Sartori, Samantha, additional, Spirito, Alessandro, additional, Vogel, Birgit, additional, Nicolas, Johny, additional, Smith, Kenneth, additional, Baber, Usman, additional, Yan, Ruiqi, additional, Kamaleldin, Karim, additional, Vijay, Pooja, additional, Guthrie, Jeffers, additional, Khera, Sahil, additional, Sweeny, Joseph M., additional, Sharma, Samin K., additional, Kini, Annapoorna Subhash, additional, Krishnamoorthy, Parasuram Melarcode, additional, and Dangas, George D., additional

Published
2023
Full Text
View/download PDF

23. Personalized Approaches to Antiplatelet Treatment for Cardiovascular Diseases: An Umbrella Review

Author

Oliva,Angelo, Cao,Davide, Spirito,Alessandro, Nicolas,Johny, Pileggi,Brunna, Kamaleldin,Karim, Vogel,Birgit, Mehran,Roxana, Oliva,Angelo, Cao,Davide, Spirito,Alessandro, Nicolas,Johny, Pileggi,Brunna, Kamaleldin,Karim, Vogel,Birgit, and Mehran,Roxana

Abstract

Angelo Oliva,1,2 Davide Cao,1,3 Alessandro Spirito,1 Johny Nicolas,1 Brunna Pileggi,1,4 Karim Kamaleldin,1 Birgit Vogel,1 Roxana Mehran1 1The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York City, NY, USA; 2Cardio Center, Humanitas Research Hospital IRCCS Rozzano, Milan, Italy; 3Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), Italy; 4Department of Cardiopneumonology, Heart Institute of the University of Sao Paulo, Sao Paulo, BrazilCorrespondence: Roxana Mehran, Tel +1-212-659-9649, Email roxana.mehran@mountsinai.orgAbstract: Antiplatelet therapy is the cornerstone of antithrombotic prevention in patients with established atherosclerosis, since it has been proven to reduce coronary, cerebrovascular, and peripheral thrombotic events. However, the protective effect of antiplatelet agents is counterbalanced by an increase of bleeding events that impacts on patients’ mortality and morbidity. Over the last years, great efforts have been made toward personalized antithrombotic strategies according to the individual bleeding and ischemic risk profile, aiming to maximizing the net clinical benefit. The development of risk scores, consensus definitions, and the new promising artificial intelligence tools, as well as the assessment of platelet responsiveness using platelet function and genetic testing, are now part of an integrated approach to tailored antithrombotic management. Moreover, novel strategies are available including dual antiplatelet therapy intensity and length modulation in patients undergoing myocardial revascularization, the use of P2Y12 inhibitor monotherapy for long-term secondary prevention, the implementation of parenteral antiplatelet agents in high-ischemic risk clinical settings, and combination of antiplatelet agents with low-dose factor Xa inhibitors (dual pathway inhibition) in patients suffering from polyvascular disease. This review summarizes the currently availa

Published
2023

24. Predictors of All-Cause Mortality After Successful Transcatheter Aortic Valve Implantation in Patients With Atrial Fibrillation

Author

Yamamoto, Masanori, Hayashida, Kentaro, Hengstenberg, Christian, Watanabe, Yusuke, Van Mieghem, Nicolas M., Jin, James, Saito, Shigeru, Valgimigli, Marco, Nicolas, Johny, Mehran, Roxana, Moreno, Raul, Kimura, Tetsuya, Chen, Cathy, Unverdorben, Martin, Dangas, George D., Yamamoto, Masanori, Hayashida, Kentaro, Hengstenberg, Christian, Watanabe, Yusuke, Van Mieghem, Nicolas M., Jin, James, Saito, Shigeru, Valgimigli, Marco, Nicolas, Johny, Mehran, Roxana, Moreno, Raul, Kimura, Tetsuya, Chen, Cathy, Unverdorben, Martin, and Dangas, George D.

Abstract

Prevalent and incident atrial fibrillation are common in patients who undergo transcatheter aortic valve implantation and are associated with impaired postprocedural outcomes, including mortality. We determined predictors of long-term mortality in patients with atrial fibrillation after successful transcatheter aortic valve implantation. The EdoxabaN Versus standard of care and theIr effectS on clinical outcomes in pAtients havinG undergonE Transcatheter Aortic Valve Implantation–Atrial Fibrillation (ENVISAGE-TAVI AF) trial (NCT02943785) was a multicenter, prospective, randomized controlled trial in patients with prevalent or incident atrial fibrillation after successful transcatheter aortic valve implantation who received edoxaban or vitamin K antagonists. A Cox proportional hazard model was performed to identify predictors of all-cause mortality using a stepwise approach for multiple regression analysis. In addition, we assessed the performance of different risk scores and prediction models using ENVISAGE-TAVI AF data. Of 1,426 patients in ENVISAGE-TAVI AF, 178 (12.5%) died during the follow-up period (median 548 days). Our stepwise approach identified greater risk of mortality with older age, impaired renal function, nonparoxysmal atrial fibrillation, excessive alcohol use, New York Heart Association heart failure class III/IV, peripheral artery disease, and history of major bleeding or predisposition to bleeding. The present model (concordance statistic [c-statistic] 0.67) was a better discriminator than were other frequently used risk scores, such as the Society of Thoracic Surgeons score (c-statistic 0.56); Congestive heart failure, Hypertension, Age ≥75, Diabetes, Stroke, Vascular disease, Age 65 to 74 years, and Sex category (CHA2DS2-VASc) score (c-statistic 0.54); or Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile international normalized ratio, Elderly, and Drugs/alcohol concomitantly

Published
2023

25. Safety and efficacy of ticagrelor monotherapy according to drug-eluting stent type: the TWILIGHT-STENT study

Author

Dangas, George, Baber, Usman, Sharma, Samin, Giustino, Gennaro, Sartori, Samantha, Nicolas, Johny, Goel, Ridhima, Mehta, Shamir, Cohen, David J., Angiolillo, Dominick J., Zhang, Zhongjie, Camaj, Anton, Cao, Davide, Briguori, Carlo, Dudek, Dariusz, Escaned, Javier, Huber, Kurt, Collier, Timothy, Kornowski, Ran, Kunadian, Vijay, Moliterno, David J., Ohman, E. Magnus, Weisz, Giora, Gil, Robert, Krucoff, Mitchell W., Kaul, Upendra, Oldroyd, Keith G., Sardella, Gennaro, Shlofmitz, Richard, Witzenbichler, Bernhard, Kastrati, Adnan, Han, Ya-ling, Steg, Philippe Gabriel, Pocock, Stuart, Gibson, C. Michael, and Mehran, Roxana

Subjects
Ticagrelor, Percutaneous Coronary Intervention, Treatment Outcome, Clinical Research, Humans, Drug-Eluting Stents, Stents, Everolimus, Cardiology and Cardiovascular Medicine, Platelet Aggregation Inhibitors
Abstract

BACKGROUND: In the TWILIGHT trial, ticagrelor monotherapy after a short course of dual antiplatelet therapy (DAPT) was shown to be a safe bleeding avoidance strategy in high-risk patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES). AIMS: The aim of this study was to evaluate the effects of ticagrelor monotherapy after three-month DAPT in patients undergoing PCI, according to DES type. METHODS: In the current sub-analysis from TWILIGHT, patients were stratified into three groups based on DES type: durable polymer everolimus-eluting stents (DP-EES), durable polymer zotarolimus-eluting stents (DP-ZES), and biodegradable polymer DES (BP-DES). Bleeding and ischaemic outcomes were assessed at one year after randomisation. RESULTS: Out of 5,769 patients, 3,014 (52.2%) had DP-EES, 1,350 (23.4%) had DP-ZES and 1,405 (24.4%) had BP-DES. Compared with ticagrelor plus aspirin, ticagrelor monotherapy had significantly lower BARC type 2, 3 or 5 bleeding compared with DAPT; DP-EES (3.8% vs 6.7%; HR 0.56, 95% CI: 0.41-0.78), DP-ZES (4.6% vs 6.9%; HR 0.66, 95% CI: 0.42-1.04) and BP-DES (4.2% vs 7.9%; HR 0.52, 95% CI: 0.33-0.81; p(interaction)=0.76). Ticagrelor monotherapy resulted in similar rates of death, MI, or stroke: DP-EES (4.2% vs 4.3%; HR 0.97; 95% CI: 0.68-1.37); DP-ZES (4.1% vs 3.1%; HR 1.32; 95% CI: 0.75-2.33); BP-DES (3.9% vs 4.2%; HR 0.92; 95% CI: 0.54-1.55; p(interaction)=0.60). In both unadjusted and covariate-adjusted analyses, DES type was not associated with any differences in ischaemic or bleeding complications. CONCLUSIONS: As compared with ticagrelor plus aspirin, ticagrelor monotherapy after a short DAPT duration lowered bleeding complications without increasing the ischaemic risk, irrespective of DES type. We observed no significant differences among DES types.

Published
2022

26. Ticagrelor with and without aspirin in patients with a prior coronary artery bypass graft undergoing percutaneous coronary intervention: the TWILIGHT-CABG study

Author

Sardella, Gennaro, primary, Beerkens, Frans J., additional, Dangas, George, additional, Cao, Davide, additional, Baber, Usman, additional, Sartori, Samantha, additional, Cohen, David J., additional, Briguori, Carlo, additional, Gil, Robert, additional, Nicolas, Johny, additional, Zhang, Zhongjie, additional, Dudek, Dariusz, additional, Kunadian, Vijay, additional, Kornowski, Ran, additional, Weisz, Giora, additional, Claessen, Bimmer, additional, Marx, Steven, additional, Escaned, Javier, additional, Huber, Kurt, additional, Collier, Timothy, additional, Moliterno, David J., additional, Ohman, E. Magnus, additional, Krucoff, Mitchell W., additional, Kastrati, Adnan, additional, Steg, Phillipe Gabriel, additional, Angiolillo, Dominick J., additional, Mehta, Shamir, additional, Shlofmitz, Richard, additional, Sharma, Samin, additional, Pocock, Stuart, additional, Gibson, Charles Michael, additional, and Mehran, Roxana, additional

Published
2022
Full Text
View/download PDF

28. Antithrombotic strategy variability in atrial fibrillation and obstructive coronary disease revascularised with percutaneous coronary intervention: primary results from the AVIATOR 2 international registry

Author

Chandrasekhar, Jaya, primary, Baber, Usman, additional, Sartori, Samantha, additional, Goel, Ridhima, additional, Nicolas, Johny, additional, Vogel, Birgit, additional, Snyder, Clayton, additional, Kini, Annapoorna, additional, Briguori, Carlo, additional, Witzenbichler, Bernhard, additional, Iakovou, Ioannis, additional, Sardella, Gennaro, additional, Marzo, Kevin, additional, DeFranco, Anthony, additional, Stuckey, Thomas, additional, Chieffo, Alaide, additional, Colombo, Antonio, additional, Shlofmitz, Richard, additional, Capodanno, Davide, additional, Dangas, George, additional, Pocock, Stuart, additional, and Mehran, Roxana, additional

Published
2022
Full Text
View/download PDF

30. TCT-4 Dual Antiplatelet Therapy for 1 Versus 3 Months in Women and Men at High Bleeding Risk Undergoing Drug-Eluting Stent Implantation

Author

Nicolas, Johny, primary, Mehran, Roxana, additional, Sartori, Samantha, additional, Snyder, Clayton, additional, Spirito, Alessandro, additional, Hermiller, James, additional, Makkar, Raj, additional, Bangalore, Sripal, additional, Angiolillo, Dominick, additional, Ge, Junbo, additional, Vogel, Birgit, additional, Saito, Shigeru, additional, Cao, Davide, additional, Guthrie, Jeffers, additional, Neumann, Franz-Josef, additional, and Bhatt, Deepak, additional

Published
2022
Full Text
View/download PDF

31. TCT-158 Pooled Analysis of Patients Undergoing Complex PCI With the Dual-Therapy COMBO Stent: The MEGA-COMBO Complex-PCI Analysis

Author

Beerkens, Frans, primary, Cao, Davide, additional, Vogel, Birgit, additional, Nardin, Matteo, additional, Sartori, Samantha, additional, Zhang, Zhongjie, additional, Nicolas, Johny, additional, Claessen, Bimmer, additional, Power, David, additional, Edens, Madison, additional, Feldman, Daniel, additional, and Dangas, George, additional

Published
2022
Full Text
View/download PDF

32. TCT-13 Ticagrelor Monotherapy in Patients With Peripheral Artery Disease Undergoing PCI

Author

Spirito, Alessandro, primary, Cao, Davide, additional, Sartori, Samantha, additional, Zhang, Zhongjie, additional, Nicolas, Johny, additional, Cohen, David, additional, Angiolillo, Dominick, additional, Briguori, Carlo, additional, Vogel, Birgit, additional, Collier, Timothy, additional, Dudek, Dariusz, additional, Escaned, Javier, additional, Sharma, Samin, additional, Farhan, Serdar, additional, Huber, Kurt, additional, Kastrati, Adnan, additional, Kornowski, Ran, additional, Krucoff, Mitchell, additional, Kunadian, Vijay, additional, Mehta, Shamir, additional, Moliterno, David, additional, Ohman, E. Magnus, additional, Sardella, Gennaro, additional, Shlofmitz, Richard, additional, Steg, Philippe, additional, Witzenbichler, Bernhard, additional, Han, Yaling, additional, Pocock, Stuart, additional, Dangas, George, additional, and Mehran, Roxana, additional

Published
2022
Full Text
View/download PDF

33. TCT-566 Impact of Sex on Risk for Adverse Events Associated With Polyvascular Disease in Patients After PCI

Author

Jou, Stephanie, primary, Vogel, Birgit, additional, Snyder, Clayton, additional, Sartori, Samantha, additional, Farhan, Serdar, additional, Nicolas, Johny, additional, Cao, Davide, additional, Moreno, Pedro, additional, Sweeny, Joseph, additional, Krishnan, Prakash, additional, Dangas, George, additional, Kini, Annapoorna, additional, and Sharma, Samin, additional

Published
2022
Full Text
View/download PDF

38. Imaging in Percutaneous Coronary Intervention

Author

Satish, Mohan, primary, Roumeliotis, Anastasios, primary, Power, David, primary, Camaj, Anton, primary, Nicolas, Johny, primary, Feldman, Daniel, primary, Jones, Davis, primary, Yasumura, Keisuke, primary, Beerkens, Frans, primary, Suleman, Saman, primary, and Dangas, George, primary

Published
2022
Full Text
View/download PDF

40. C-57 | Prevalence and Outcomes of Early Menopause in Women undergoing Transcatheter Aortic Valve Replacement: Insights from the WIN-TAVI Registry

Author

Edens, Madison, primary, Watanabe, Yusuke, additional, Nicolas, Johny, additional, Sartori, Samantha, additional, Snyder, Clayton, additional, Presbitero, Patrizia, additional, Petronio, A. Sonia, additional, Mehilli, Julinda, additional, Van Mieghem, Nicolas M., additional, Lefevre, Thierry, additional, Chandrasekhar, Jaya, additional, Vogel, Birgit, additional, Spirito, Alessandro, additional, Tchetche, Didier, additional, Mikhail, Ghada, additional, Sharma, Samin K., additional, Chieffo, Alaide, additional, Dangas, George D., additional, Morice, Marie-Claude, additional, and Mehran, Roxana, additional

Published
2022
Full Text
View/download PDF

41. A-54 | Efficacy and Safety of P2Y12 Inhibitor Monotherapy After Complex PCI: A Collaborative Systematic Review and Meta-Analysis

Author

Nicolas, Johny, primary, Mehran, Roxana, additional, Chiarito, Mauro, additional, Pivato, Carlo Andrea, additional, Spirito, Alessandro, additional, Cao, Davide, additional, Guistino, Gennaro, additional, Beerkens, Frans, additional, Camaj, Anton, additional, Vogel, Birgit, additional, Sartori, Samantha, additional, Baber, Usman, additional, Yamamoto, Ko, additional, Kimura, Takeshi, additional, Kim, Byeong-Keuk, additional, and Dangas, George D., additional

Published
2022
Full Text
View/download PDF

42. Two-year clinical outcomes after successful transcatheter aortic valve implantation with balloon-expandable versus self-expanding valves: A subanalysis of the GALILEO trial

Author

Okuno, Taishi, Dangas, George D., Hengstenberg, Christian, Sartori, Samantha, Herrmann, Howard C., de Winter, Robert, Gilard, Martine, Tchetche, Didier, Moellmann, Helge, Makkar, Raj R., Baldus, Stephan, De Backer, Ole, Bendz, Bjorn, Kini, Annapoorna, von Lewinski, Dirk, Mack, Michael, Moreno, Raul, Schaefer, Ulrich, Woehrle, Jochen, Seeger, Julia, Snyder, Clayton, Nicolas, Johny, Tijssen, Jan G. P., Welsh, Robert C., Vranckx, Pascal, Valgimigli, Marco, Mehran, Roxana, Kapadia, Samir, Sondergaard, Lars, Windecker, Stephan, Okuno, Taishi, Dangas, George D., Hengstenberg, Christian, Sartori, Samantha, Herrmann, Howard C., de Winter, Robert, Gilard, Martine, Tchetche, Didier, Moellmann, Helge, Makkar, Raj R., Baldus, Stephan, De Backer, Ole, Bendz, Bjorn, Kini, Annapoorna, von Lewinski, Dirk, Mack, Michael, Moreno, Raul, Schaefer, Ulrich, Woehrle, Jochen, Seeger, Julia, Snyder, Clayton, Nicolas, Johny, Tijssen, Jan G. P., Welsh, Robert C., Vranckx, Pascal, Valgimigli, Marco, Mehran, Roxana, Kapadia, Samir, Sondergaard, Lars, and Windecker, Stephan

Abstract

Background Midterm data comparing clinical outcomes after successful implantation of self-expanding and balloon-expandable transcatheter heart valves (THV) are limited. We aimed to compare 2-year outcomes after successful transcatheter aortic valve implantation (TAVI) with the Edwards balloon-expandable or the Medtronic self-expanding THV. Methods Two-year outcomes were analyzed according to the implanted THV in the GALILEO trial. Major adverse cardiac and cerebrovascular events (MACCE) was a composite of all-cause death or thromboembolic events including stroke, myocardial infarction, symptomatic valve thrombosis, systemic embolism, deep-vein thrombosis, or pulmonary embolism. Results Among 1644 patients recruited in 136 centers across 16 countries between 2015 and 2018, 499 received a self-expanding and 757 patients received a balloon-expandable THV. Patients treated with a self-expanding THV were more likely to be female, and had higher surgical risk, lower hemoglobin levels, and more frequent valve-in-valve procedures than those with a balloon-expandable THV. After multivariable adjustment, there were no significant differences in major clinical outcomes between self-expanding versus balloon-expandable THV: MACCE (17.0% vs. 13.4%, adjusted-hazard ratios [HR] 1.18, 95% confidence intervals [CI]: 0.82-1.69); all-cause death (11.4% vs. 9.3%, adjusted-HR 1.26; 95% CI: 0.78-2.05); cardiovascular death (8.5% vs. 4.0%, adjusted-HR 1.53; 95% CI: 0.82-2.86), any stroke (5.1% vs. 3.7%, adjusted-HR 0.86; 95% CI: 0.43-1.73); major or life-threatening bleeding (5.9% vs. 6.8%, adjusted-HR 0.93; 95% CI: 0.53-1.63). Clinical Trial Registration: . NCT02556203. Conclusions Two-year follow-up data from the GALILEO trial indicate that successful TAVI either with self-expanding or balloon-expandable THVs according to physician discretion did not show difference in rates of MACCE.

Published
2022

43. Two-year clinical outcomes after successful transcatheter aortic valve implantation with balloon-expandable versus self-expanding valves:A subanalysis of the GALILEO trial

Author

Okuno, Taishi, Dangas, George D., Hengstenberg, Christian, Sartori, Samantha, Herrmann, Howard C., de Winter, Robert, Gilard, Martine, Tchétché, Didier, Möllmann, Helge, Makkar, Raj R., Baldus, Stephan, De Backer, Ole, Bendz, Bjørn, Kini, Annapoorna, von Lewinski, Dirk, Mack, Michael, Moreno, Raúl, Schäfer, Ulrich, Wöhrle, Jochen, Seeger, Julia, Snyder, Clayton, Nicolas, Johny, Tijssen, Jan G.P., Welsh, Robert C., Vranckx, Pascal, Valgimigli, Marco, Mehran, Roxana, Kapadia, Samir, Sondergaard, Lars, Windecker, Stephan, Okuno, Taishi, Dangas, George D., Hengstenberg, Christian, Sartori, Samantha, Herrmann, Howard C., de Winter, Robert, Gilard, Martine, Tchétché, Didier, Möllmann, Helge, Makkar, Raj R., Baldus, Stephan, De Backer, Ole, Bendz, Bjørn, Kini, Annapoorna, von Lewinski, Dirk, Mack, Michael, Moreno, Raúl, Schäfer, Ulrich, Wöhrle, Jochen, Seeger, Julia, Snyder, Clayton, Nicolas, Johny, Tijssen, Jan G.P., Welsh, Robert C., Vranckx, Pascal, Valgimigli, Marco, Mehran, Roxana, Kapadia, Samir, Sondergaard, Lars, and Windecker, Stephan

Abstract

Background: Midterm data comparing clinical outcomes after successful implantation of self-expanding and balloon-expandable transcatheter heart valves (THV) are limited. We aimed to compare 2-year outcomes after successful transcatheter aortic valve implantation (TAVI) with the Edwards balloon-expandable or the Medtronic self-expanding THV. Methods: Two-year outcomes were analyzed according to the implanted THV in the GALILEO trial. Major adverse cardiac and cerebrovascular events (MACCE) was a composite of all-cause death or thromboembolic events including stroke, myocardial infarction, symptomatic valve thrombosis, systemic embolism, deep-vein thrombosis, or pulmonary embolism. Results: Among 1644 patients recruited in 136 centers across 16 countries between 2015 and 2018, 499 received a self-expanding and 757 patients received a balloon-expandable THV. Patients treated with a self-expanding THV were more likely to be female, and had higher surgical risk, lower hemoglobin levels, and more frequent valve-in-valve procedures than those with a balloon-expandable THV. After multivariable adjustment, there were no significant differences in major clinical outcomes between self-expanding versus balloon-expandable THV: MACCE (17.0% vs. 13.4%, adjusted-hazard ratios [HR] 1.18, 95% confidence intervals [CI]: 0.82−1.69); all-cause death (11.4% vs. 9.3%, adjusted-HR 1.26; 95% CI: 0.78−2.05); cardiovascular death (8.5% vs. 4.0%, adjusted-HR 1.53; 95% CI: 0.82−2.86), any stroke (5.1% vs. 3.7%, adjusted-HR 0.86; 95% CI: 0.43−1.73); major or life-threatening bleeding (5.9% vs. 6.8%, adjusted-HR 0.93; 95% CI: 0.53−1.63). Clinical Trial Registration: https://www.clinicaltrials.gov. NCT02556203. Conclusions: Two-year follow-up data from the GALILEO trial indicate that successful TAVI either with self-expanding or balloon-expandable THVs according to physician discretion did not show difference in rates of MACCE.

Published
2022

44. Evolution of drug-eluting coronary stents: a back-and-forth journey from the bench to bedside.

Author

Nicolas, Johny, Pivato, Carlo Andrea, Chiarito, Mauro, Beerkens, Frans, Cao, Davide, and Mehran, Roxana

Subjects
*SURGICAL stents, *DRUG-eluting stents, *TRANSLUMINAL angioplasty, *CORONARY artery disease, *DRUG coatings
Abstract

Coronary stents have revolutionized the treatment of coronary artery disease. Compared with balloon angioplasty, bare-metal stents (BMSs) effectively prevented abrupt vessel closure but were limited by in-stent restenosis (ISR) due to smooth muscle cell proliferation and neointimal hyperplasia. The first-generation drug-eluting stent (DES), with its antiproliferative drug coating, offered substantial advantages over BMSs as it mitigated the risk of ISR. Nonetheless, they had several design limitations that increased the risk of late stent thrombosis. Significant advances in stent design, including thinner struts, enhanced polymers' formulation, and more potent antiproliferative agents, have led to the introduction of new-generation DES with a superior safety profile. Cardiologists have over 20 different DES types to choose from, each with its unique features and characteristics. This review highlights the evolution of stent design and summarizes the clinical data on the different stent types. We conclude by discussing the clinical implications of stent design in high-risk subsets of patients. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

45. IMPACT OF CORONARY ARTERY DISEASE ON CLINICAL OUTCOMES AFTER TAVR: INSIGHTS FROM THE BRAVO-3 RANDOMIZED TRIAL

Author

Feldman, Daniel, primary, Cao, Davide, additional, Nicolas, Johny, additional, Hengstenberg, Christian, additional, Zhang, Zhongie, additional, Sartori, Samantha, additional, Beerkens, Frans, additional, Pivato, Carlo Andrea, additional, Chiarito, Mauro, additional, Satish, Mohan, additional, Jones, Davis B., additional, Iyer, Divya, additional, Power, David, additional, Chen, Huazhen, additional, Camaj, Anton, additional, Razuk, Victor, additional, Roumeliotis, Anastasios, additional, Jeger, Raban V., additional, Violini, Roberto, additional, Ferrari, Markus, additional, Mehran, Roxana, additional, and Dangas, George D., additional

Published
2022
Full Text
View/download PDF

46. TICAGRELOR MONOTHERAPY AFTER PCI ACROSS THE SPECTRUM OF HIGH-RISK PATIENTS: A DEEP DIVE INTO THE TWILIGHT TRIAL

Author

Nicolas, Johny, primary, Steg, Philippe Gabriel, additional, Cao, Davide, additional, Baber, Usman, additional, Sartori, Samantha, additional, Zhang, Zhongjie, additional, Sharma, Samin K., additional, Cohen, David J., additional, Angiolillo, Dominick J., additional, Collier, Tim, additional, Escaned, Javier, additional, Gil, Robert, additional, Beerkens, Frans, additional, Džavík, Vladimír, additional, Henry, Timothy D., additional, Huber, Kurt, additional, Kornowski, Ran, additional, Ohman, E Magnus, additional, Krucoff, Mitchell W., additional, Kunadian, Vijay, additional, Pocock, Stuart J., additional, Gibson, Charles Michael, additional, Dangas, George D., additional, and Mehran, Roxana, additional

Published
2022
Full Text
View/download PDF

47. PREDICTORS OF ANTIPLATELET CESSATION IN A REAL-WORLD PATIENT POPULATION WITH CORONARY STENTS UNDERGOING NONCARDIAC SURGERY

Author

Koshy, Anoop Ninan, primary, Cao, Davide, additional, Sartori, Samantha, additional, Kini, Annapoorna Subhash, additional, Zhang, Zhongjie, additional, Claessen, Bimmer, additional, Nardin, Matteo, additional, Pivato, Carlo Andrea, additional, Chandiramani, Rishi, additional, Giustino, Gennaro, additional, Chiarito, Mauro, additional, Nicolas, Johny, additional, Sharma, Samin K., additional, and Mehran, Roxana, additional

Published
2022
Full Text
View/download PDF

48. PROGNOSTIC VALUE OF HIGH SENSITIVITY C-REACTIVE PROTEIN AMONG CHRONIC KIDNEY DISEASE PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION

Author

Jones, Davis B., primary, Pivato, Carlo, additional, Cao, Davide, additional, Sartori, Samantha, additional, Nicolas, Johny, additional, Beerkens, Frans, additional, Razuk, Victor, additional, Feldman, Daniel, additional, Satish, Mohan, additional, Snyder, Clayton, additional, Giustino, Gennaro, additional, Krishnan, Prakash, additional, Barman, Nitin, additional, Sweeny, Joseph M., additional, Baber, Usman, additional, Dangas, George D., additional, Sharma, Samin K., additional, Kini, Annapoorna Subhash, additional, and Mehran, Roxana, additional

Published
2022
Full Text
View/download PDF

49. IMPACT OF CHRONIC THROMBOCYTOPENIA ON CLINICAL OUTCOMES AFTER TAVR: INSIGHTS FROM THE BRAVO-3 RANDOMIZED TRIAL

Author

Feldman, Daniel, primary, Cao, Davide, additional, Razuk, Victor, additional, Nicolas, Johny, additional, Hengstenberg, Christian, additional, Zhang, Zhongie, additional, Sartori, Samantha, additional, Beerkens, Frans, additional, Pivato, Carlo Andrea, additional, Chiarito, Mauro, additional, Jones, Davis B., additional, Satish, Mohan, additional, Roumeliotis, Anastasios, additional, Power, David, additional, Camaj, Anton, additional, Jeger, Raban V., additional, Violini, Roberto, additional, Ferrari, Markus, additional, Mehran, Roxana, additional, and Dangas, George D., additional

Published
2022
Full Text
View/download PDF

50. Colchicine in Cardiovascular Disease: In Depth Review

Author

Deftereos, Spyridon G., Beerkens, Frans J., Shah, Binita, Giannopoulos, George, Vrachatis, Dimitrios A., Giotaki, Sotiria G., Siasos, Gerasimos, Nicolas, Johny, Arnott, Clare, Patel, Sanjay, Parsons, Mark, Tardif, Jean-Claude, Kovacic, Jason C., and Dangas, George D.

Subjects
Cardiovascular Diseases, Humans, Colchicine, Article, Gout Suppressants
Abstract

Inflammation plays a prominent role in the development of atherosclerosis and other cardiovascular diseases, and anti-inflammatory agents may improve cardiovascular outcomes. For years, colchicine has been used as a safe and well-tolerated agent in diseases such as gout and familial Mediterranean fever. The widely available therapeutic has several anti-inflammatory effects however that have proven effective in a broad spectrum of cardiovascular diseases as well. It is considered standard-of-care therapy for pericarditis, and several clinical trials have evaluated its role in pericarditis, post-operative- and post-ablation atrial fibrillation, post-pericardiotomy syndrome, coronary artery disease, percutaneous coronary interventions, and cerebrovascular disease. We aim to summarize colchicine’s pharmacodynamics and the mechanism behind its anti-inflammatory effect, outline thus far accumulated evidence on treatment with colchicine in cardiovascular disease, and present ongoing randomized clinical trials. We also emphasize real-world clinical implications that should be considered on the basis of the merits and limitations of completed trials. Altogether, colchicine’s simplicity, low cost, and effectiveness may provide an important addition to other standard cardiovascular therapies. Ongoing studies will address complementary questions pertaining to the use of low-dose colchicine for the treatment of cardiovascular disease.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results